As of 2026-10-14, the EV/EBITDA ratio of Arcturus Therapeutics Holdings Inc (ARCT) is -1.51. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARCT's latest enterprise value is 150.41 mil USD. ARCT's TTM EBITDA according to its financial statements is -99.55 mil USD. Dividing these 2 quantities gives us the above ARCT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.5x - 17.5x | 16.7x |
| Forward P/E multiples | 18.4x - 22.2x | 20.3x |
| Fair Price | (57.71) - (54.56) | (58.06) |
| Upside | -579.7% - -553.5% | -582.7% |
| Date | EV/EBITDA |
| 2026-10-12 | -1.68 |
| 2026-10-09 | -2.00 |
| 2026-10-08 | -1.75 |
| 2026-10-07 | -1.72 |
| 2026-10-06 | -1.79 |
| 2026-10-05 | -2.26 |
| 2026-10-02 | -1.80 |
| 2026-10-01 | -1.85 |
| 2026-09-30 | -1.98 |
| 2026-09-29 | -1.99 |
| 2026-09-28 | -2.20 |
| 2026-09-25 | -2.03 |
| 2026-09-24 | -2.11 |
| 2026-09-23 | -1.87 |
| 2026-09-22 | -2.18 |
| 2026-09-21 | -2.27 |
| 2026-09-18 | -2.65 |
| 2026-09-17 | -2.91 |
| 2026-09-16 | -2.53 |
| 2026-09-15 | -2.60 |
| 2026-09-14 | -2.44 |
| 2026-09-11 | -2.28 |
| 2026-09-10 | -2.07 |
| 2026-09-09 | -2.28 |
| 2026-09-08 | -2.54 |
| 2026-09-04 | -2.59 |
| 2026-09-03 | -2.52 |
| 2026-09-02 | -2.86 |
| 2026-09-01 | -2.71 |
| 2026-08-31 | -2.29 |
| 2026-08-28 | -2.41 |
| 2026-08-27 | -2.69 |
| 2026-08-26 | -2.60 |
| 2026-08-25 | -2.48 |
| 2026-08-24 | -2.17 |
| 2026-08-21 | -1.92 |
| 2026-08-20 | -1.21 |
| 2026-08-19 | -1.01 |
| 2026-08-18 | -0.42 |
| 2026-08-17 | -0.40 |
| 2026-08-14 | -0.43 |
| 2026-08-13 | -0.32 |
| 2026-08-12 | -0.25 |
| 2026-08-11 | -0.22 |
| 2026-08-10 | -0.09 |
| 2026-08-07 | -0.19 |
| 2026-08-06 | 0.19 |
| 2026-08-05 | 0.14 |
| 2026-08-04 | 0.15 |
| 2026-08-03 | 0.21 |